Frederick G. Hayden

Frederick G. Hayden's AcademicInfluence.com Rankings

Frederick G. Hayden

Philosophy

#3397

World Rank

#5502

Historical Rank

Logic

#1134

World Rank

#1799

Historical Rank

philosophy Degrees

Frederick G. Hayden

Biology

#4240

World Rank

#6356

Historical Rank

Virology

#70

World Rank

#73

Historical Rank

Microbiology

#138

World Rank

#163

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Frederick G. Hayden's Degrees

Doctorate Medicine University of Virginia
PhD Microbiology University of Virginia

Why Is Frederick G. Hayden Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Frederick G. Hayden's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A novel coronavirus outbreak of global health concern (2020) (5799)
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 (2020) (4463)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial (2020) (2820)
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) (2020) (1956)
Avian influenza A (H5N1) infection in humans. (2005) (1214)
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. (2010) (994)
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome (2017) (944)
Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza (2000) (916)
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. (1998) (913)
Resistant influenza A viruses in children treated with oseltamivir: descriptive study (2004) (806)
Oral oseltamivir treatment of influenza in children (2001) (714)
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. (1998) (684)
Influenza virus neuraminidase inhibitors (2000) (684)
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections (1997) (668)
Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. (2009) (666)
Kinetics of Influenza A Virus Infection in Humans (2006) (628)
Update on avian influenza A (H5N1) virus infection in humans. (2008) (593)
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. (1999) (562)
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. (2003) (518)
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents (2018) (506)
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) (2020) (456)
Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. (1999) (450)
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. (2000) (435)
Influenza in the acute hospital setting. (2002) (432)
Nonpharmaceutical Interventions for Pandemic Influenza, National and Community Measures (2006) (429)
Influenza vaccination of health care workers in hospitals--a review of studies on attitudes and predictors. (2009) (423)
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. (2000) (394)
Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing☆ (2004) (387)
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. (1989) (382)
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. (2002) (382)
Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use (2006) (379)
Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. (2000) (371)
WRITING COMMITTEE OF THE WORLD HEALTH ORGANIZATION (WHO) CONSULTATION ON HUMAN INFLUENZA A/H5. AVIAN INFLUENZA A (H5N1) INFECTION IN HUMANS (2005) (363)
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus (2013) (352)
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. (2000) (350)
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. (2001) (347)
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. (2004) (333)
Symptom pathogenesis during acute influenza: Interleukin‐6 and Other cytokine responses (2001) (331)
Nonpharmaceutical Interventions for Pandemic Influenza, International Measures (2006) (314)
Frequency and natural history of rhinovirus infections in adults during autumn (1997) (313)
Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir (2003) (313)
Acyclovir with and without Prednisone for the Treatment of Herpes Zoster (1996) (297)
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. (1999) (294)
Preventing Nosocomial Influenza by Improving the Vaccine Acceptance Rate of Clinicians (2004) (288)
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. (1996) (288)
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. (2018) (287)
Detection of Rhinovirus, Respiratory Syncytial Virus, and Coronavirus Infections in Acute Otitis Media by Reverse Transcriptase Polymerase Chain Reaction (1998) (286)
Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. (1993) (274)
Developing new antiviral agents for influenza treatment: what does the future hold? (2009) (268)
The hidden burden of influenza: A review of the extra‐pulmonary complications of influenza infection (2017) (263)
Plaque inhibition assay for drug susceptibility testing of influenza viruses (1980) (260)
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. (2006) (258)
Rhinovirus and the lower respiratory tract† (2004) (254)
Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. (1992) (253)
Efficacy and Safety of Oral Pleconaril for Treatment of Colds Due to Picornaviruses in Adults: Results of 2 Double-Blind, Randomized, Placebo-Controlled Trials (2003) (248)
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. (2019) (248)
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study (2019) (229)
Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors (2005) (226)
Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection (2006) (225)
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. (1997) (221)
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia (2016) (219)
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update (2021) (218)
Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network (2003) (216)
Middle East Respiratory Syndrome. (2017) (211)
Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers (2003) (207)
Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants (2001) (206)
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. (1999) (204)
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol (2015) (199)
Rhinovirus and Coronavirus Infection-Associated Hospitalizations among Older Adults (2002) (199)
Critical care management of adults with community-acquired severe respiratory viral infection (2020) (198)
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. (2012) (195)
Writing Committee of the Second World Health Organization (WHO) Consultation on Clinical Aspects of Human Infection with Avian Influenza A(H5N1) Virus (2007) (194)
The immunogenicity of influenza virus vaccine in solid organ transplant recipients. (1996) (193)
Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. (1995) (192)
Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. (1999) (191)
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus (2006) (186)
Picornavirus infections in children diagnosed by RT‐PCR during longitudinal surveillance with weekly sampling: Association with symptomatic illness and effect of season (2006) (186)
Antiviral resistance in influenza viruses--implications for management and pandemic response. (2006) (181)
Etiology of acute conjunctivitis in children. (1981) (180)
Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR (1997) (177)
Development of common cold symptoms following experimental rhinovirus infection is related to prior stressful life events. (1992) (172)
Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. (2007) (170)
Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. (1986) (170)
Emerging influenza antiviral resistance threats. (2011) (167)
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. (2002) (164)
Viral infections in immunocompromised patients: what's new with respiratory viruses? (2002) (163)
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. (1981) (159)
Position statement: global neuraminidase inhibitor susceptibility network. (2001) (159)
Influenza virus polymerase inhibitors in clinical development (2019) (159)
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. (2006) (154)
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine (1991) (153)
Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. (1995) (150)
Antiviral combinations for severe influenza (2014) (148)
A novel coronavirus outbreak of global health concern - Comment - Correction (2020) (140)
Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection (1999) (138)
Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. (1998) (137)
Rhinovirus Infections in Hematopoietic Stem Cell Transplant Recipients with Pneumonia (2003) (132)
Transparent Development of the WHO Rapid Advice Guidelines (2007) (131)
Review: interventions to increase influenza vaccination among healthcare workers in hospitals (2012) (128)
Antiviral management of seasonal and pandemic influenza. (2006) (128)
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial (2020) (126)
Experimental rhinovirus challenges in adults with mild asthma: response to infection in relation to IgE. (2003) (126)
Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. (1999) (121)
Oral prednisone therapy in experimental rhinovirus infections. (1996) (118)
Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. (1987) (117)
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. (2019) (115)
Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. (1993) (115)
Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. (2017) (115)
Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. (2019) (114)
Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. (2000) (114)
A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. (1990) (114)
Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment (2005) (113)
Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza (2002) (113)
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. (2008) (111)
Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics (2015) (111)
Perspectives on antiviral use during pandemic influenza. (2001) (109)
Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics (1983) (108)
Macrolides in critically ill patients with Middle East Respiratory Syndrome (2019) (106)
Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students (1997) (105)
Acute respiratory viral infections in ambulatory children of urban northeast Brazil. (1991) (104)
In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication (2002) (104)
Antivirals targeting the polymerase complex of influenza viruses. (2019) (104)
Nasal and Otologic Effects of Experimental Influenza a Virus Infection (1994) (104)
Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults (1981) (103)
Transmission of Avian Influenza Viruses to and between Humans (2005) (101)
Relationship of Pleconaril Susceptibility and Clinical Outcomes in Treatment of Common Colds Caused by Rhinoviruses (2005) (101)
Antivirals for influenza: historical perspectives and lessons learned. (2006) (100)
Design, recruitment, and microbiological considerations in human challenge studies. (2015) (99)
Intranasal pirodavir (R77,975) treatment of rhinovirus colds (1995) (98)
Symptom Profile of Common Colds in School-Aged Children (2008) (98)
"Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. (2009) (96)
Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome (2019) (96)
Oral Oseltamivir in Human Experimental Influenza B Infection (1999) (95)
Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection (1992) (95)
Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options (2014) (94)
Prevention and treatment of influenza in immunocompromised patients. (1997) (94)
In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. (2000) (94)
How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count (2009) (92)
Respiratory nitric oxide levels in experimental human influenza. (1998) (92)
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. (2020) (91)
Zinc Gluconate Lozenges for Treating the Common Cold (1997) (89)
Effectiveness and Safety of Intranasal Ipratropium Bromide in Common Colds (1996) (89)
Alterations of the eustachian tube, middle ear, and nose in rhinovirus infection. (1989) (87)
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes (2019) (87)
Intranasal Interferon-α2, Treatment of Experimental Rhinoviral Colds (1984) (85)
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007 (2009) (85)
Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults (1985) (85)
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. (2000) (85)
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. (2008) (85)
Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial. (1992) (84)
Influenza A virus--induced acute otitis media. (1995) (84)
Enterovirus meningitis in adults. (1998) (83)
Cardiac findings during uncomplicated acute influenza in ambulatory adults. (2005) (82)
Rhinoviruses: important respiratory pathogens. (1998) (81)
Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds (1984) (81)
Open source clinical science for emerging infections (2013) (80)
Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. (1991) (80)
Increased Interleukin-6 Levels in Nasal Lavage Samples following Experimental Influenza A Virus Infection (1998) (79)
In vitro activity of zinc salts against human rhinoviruses (1987) (79)
Prevention of Nosocomial Influenza (1996) (79)
Intranasal Interferon α2 for Prevention of Rhinovirus Infection and Illness (1983) (79)
Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. (1992) (78)
Lymphocyte subsets in normal airway mucosa of the human nose. (1987) (77)
A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. (2013) (77)
Picornavirus infections: a primer for the practitioner. (2000) (77)
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. (1992) (76)
Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection (1982) (74)
Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. (1988) (72)
Peripheral blood mononuclear cell interleukin-2 and interferon-gamma production, cytotoxicity, and antigen-stimulated blastogenesis during experimental rhinovirus infection. (1990) (72)
Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages. (2001) (71)
Safety of influenza vaccine in heart transplant recipients. (1998) (71)
Respiratory viral threats (2006) (71)
Chemotherapy of rhinovirus colds (1988) (71)
End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. (2010) (70)
Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. (1989) (68)
Newer influenza antivirals, biotherapeutics and combinations (2013) (68)
Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults (1986) (67)
Viral respiratory infection in schoolchildren: effects on middle ear pressure. (2002) (67)
Clinical and epidemiological importance of influenza a viruses resistant to amantadine and rimantadine (1992) (66)
Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection: guide for field operations (2006) (65)
Modification of experimental rhinovirus colds by receptor blockade. (1988) (65)
Fatal influenza B infections: time to reexamine influenza research priorities. (2012) (65)
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. (2020) (64)
Combination antiviral therapy for influenza: predictions from modeling of human infections. (2012) (63)
Oral Pleconaril Treatment of Picornavirus-Associated Viral Respiratory Illness in Adults: Efficacy and Tolerability in Phase II Clinical Trials (2002) (62)
Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. (1994) (62)
Current research on respiratory viral infections: Fourth International Symposium (2001) (61)
Detection of human rhinovirus RNA in nasal washings by PCR. (1993) (61)
Pandemic Influenza: Is an Antiviral Response Realistic? (2004) (60)
Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. (2006) (60)
Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. (1997) (58)
Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses (2006) (58)
Effect of Hemagglutinin Glycosylation on Influenza Virus Susceptibility to Neuraminidase Inhibitors (2005) (57)
John F. Enders lecture 2006: antivirals for influenza. (2007) (57)
Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection (1993) (56)
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial (2020) (56)
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. (2020) (55)
Oral ribavirin treatment of influenza A and B (1987) (54)
Enhancement of activity against influenza viruses by combinations of antiviral agents (1980) (54)
Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro (1984) (53)
Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds (1988) (53)
Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. (1998) (52)
Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative (2013) (52)
New approaches to influenza chemotherapy. Neuraminidase inhibitors. (1998) (52)
Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. (1992) (52)
Clinical issues and research in respiratory failure from severe acute respiratory syndrome. (2005) (51)
Current Research on Influenza and other Respiratory Viruses: II International Symposium (2000) (50)
Antivirals for pandemic influenza. (1997) (50)
Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. (1992) (49)
Epidemic influenza--responding to the expected but unpredictable. (2013) (48)
Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. (1983) (48)
Combination antiviral therapy for respiratory virus infections. (1996) (48)
Ipratropium bromide treatment of experimental rhinovirus infection (1988) (48)
Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. (1996) (47)
Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection. (2002) (47)
Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. (2009) (47)
The Response of the Nasal Airway, Middle Ear, and Eustachian Tube to Experimental Rhinovirus Infection (1988) (47)
Middle ear abnormalities during natural rhinovirus colds in adults. (1993) (46)
Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. (1987) (46)
Oseltamivir resistance during treatment of H7N9 infection (2013) (46)
Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans (1994) (44)
Rapid diagnosis of influenza A and B by 24-h fluorescent focus assays (1988) (43)
Combinations of antiviral agents for treatment of influenza virus infections. (1986) (43)
Comparative susceptibilities of human embryonic fibroblasts and HeLa cells for isolation of human rhinoviruses (1996) (43)
Safety and Efficacy of Once Daily Intranasal Zanamivir in Preventing Experimental Human Influenza a Infection (1998) (42)
Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. (1980) (42)
A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. (2002) (42)
Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families. (2002) (41)
Advances in antivirals for non‐influenza respiratory virus infections (2013) (40)
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis (2020) (40)
Acute febrile cerebrovasculitis: a syndrome of unknown, perhaps rickettsial, cause. (1986) (38)
Acute encephalopathy associated with influenza A infection in adults. (2010) (38)
Influenza A (H5N1): Will It Be the Next Pandemic Influenza? Are We Ready? (2005) (38)
LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study) (2018) (38)
Vidarabine therapy for mucocutaneous herpes simplex virus infections in the immunocompromised host. (1984) (37)
Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. (1983) (37)
Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. (2005) (37)
Multiple sclerosis attacks are associated with picornavirus infections (2004) (36)
"Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion. (2006) (36)
Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. (1986) (36)
Immune response of adults to sequential influenza vaccination (1984) (36)
Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. (2017) (35)
Nasopharyngeal Reservoir of Bacterial Otitis Media and Sinusitis Pathogens in Adults during Wellness and Viral Respiratory Illness (2003) (35)
In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1 (1992) (33)
Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro (1982) (33)
Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. (1984) (32)
Herpesvirus infections in burn patients. (1994) (32)
Therapeutic options for the management of influenza. (2001) (32)
Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections. (1985) (31)
In vitro Inhibitory Activity of Soluble ICAM-1 for the Numbered Serotypes of Human Rhinovirus (1993) (31)
Localization of rhinovirus replication in vitro with in situ hybridization (1991) (30)
Antiviral Drugs (Other than Antiretrovirals) (2010) (29)
Experimental human influenza: observations from studies of influenza antivirals. (2012) (29)
Herpes simplex burn wound infections: epidemiology of a case cluster and responses to acyclovir therapy. (1985) (28)
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza (2020) (28)
Global outbreak research: harmony not hegemony (2020) (28)
Preventing the Airborne Spread of Staphylococcus aureus by Persons With the Common Cold: Effect of Surgical Scrubs, Gowns, and Masks (2007) (28)
Current research on respiratory viral infections: Third International Symposium (2001) (28)
Relapse of herpes simplex encephalitis after conventional acyclovir therapy. (1988) (28)
Comparative Susceptibility of Respiratory Viruses to Recombinant Interferons-α2b and -β (1989) (27)
Critically ill healthcare workers with the middle east respiratory syndrome (MERS): A multicenter study (2018) (27)
Ineffectiveness of Recombinant Interferon-βserine Nasal Drops for Prophylaxis of Natural Colds (1989) (27)
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit (2021) (26)
Therapeutic Effects of an Anticholinergic-Sympathomimetic Combination in Induced Rhinovirus Colds (1993) (25)
Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA. (2002) (25)
Intranasally administered atropine methonitrate treatment of experimental rhinovirus colds. (1987) (25)
Antiviral resistance in clinical practice. (1995) (25)
Pattern of nasal secretions during experimental influenza virus infection. (1996) (25)
Experimental Therapies for Ebola Virus Disease: What Have We Learned? (2017) (25)
Ebola virus disease: an update on post-exposure prophylaxis. (2017) (24)
Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults. (1988) (24)
Orthomyxoviral and paramyxoviral infections in transplant patients. (1995) (24)
Overview of the 3rd isirv-Antiviral Group Conference – advances in clinical management (2014) (23)
Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. (2005) (23)
Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. (2010) (22)
Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule (1994) (22)
Comparative anti-influenza virus activity of 2'-deoxy-2'-fluororibosides in vitro. (1993) (22)
Symptom Expression in Natural and Experimental Rhinovirus Colds (1995) (22)
Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. (1982) (21)
First International Symposium on Influenza and Other Respiratory Viruses: summary and overview (1999) (21)
Comparison of the Immulok cultureset kit and virus isolation for detection of herpes simplex virus in clinical specimens (1983) (21)
Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. (1989) (21)
Otologic and systemic manifestations of experimental influenza A virus infection in the ferret. (1995) (21)
Anti-influenza virus activity of the compound LY253963. (1990) (21)
The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. (2008) (20)
Seasonal and pandemic influenza: recommendations for preparedness in the United States. (2006) (20)
Human polymorphonuclear neutrophil functions are unaffected by human interferon-alpha 2 (1983) (20)
Clinical Virology, 3rd Edition (2010) (19)
Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. (2020) (19)
Human nasal mucosal responses to topically applied recombinant leukocyte A interferon. (1987) (18)
New Approaches to Influenza Chemotherapy (1998) (18)
Amantadine and rimantadine resistance in influenza A viruses (1994) (18)
Effect Of Ribavirin And Interferon On The Outcome Of Critically Ill Patients With Mers (2017) (18)
Hospitalizing influenza in adults. (1999) (18)
Towards improving clinical management of Middle East respiratory syndrome coronavirus infection (2014) (17)
Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds. (1989) (17)
Symposium: Questioning the Efficacy and Safety of Antihistamines in the Treatment of Upper Respiratory Infection (1988) (17)
:Clinical Virology, 2nd Edition (2002) (17)
VII International Symposium on Respiratory Viral Infections (2005) (17)
Report of the ‘Mechanisms of lung injury and immunomodulator interventions in influenza’ workshop, 21 March 2010, Ventura, California, USA* (2011) (17)
Necrotizing balanitis due to herpes simplex type 1. (1982) (16)
Counterimmunoelectrophoresis of urine for diagnosis of bacterial pneumonia in pediatric outpatients. (1983) (16)
Influenza treatment with neuraminidase inhibitors (2005) (16)
Otologic effects of interferon beta serine in experimental rhinovirus colds. (1992) (16)
Immune modulation by aspirin during experimental rhinovirus colds. (1989) (16)
Acute Encephalopathy Associated with Influenza A Infection in Adults (2010) (15)
Effects of dietary supplementation with conjugated linoleic acid on experimental human rhinovirus infection and illness (2009) (15)
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group (2021) (15)
Human influenza: Pathogenesis, clinical features, and management (2013) (15)
Editorial response: rhinovirus pneumonia--a clinical entity? (1999) (15)
Anti‐infective immunoadhesins from plants (2015) (15)
Multiple-dose pharmacokinetics of rimantadine in elderly adults (1988) (15)
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. (2003) (15)
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial (2022) (14)
Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha 2. (1983) (14)
Update on influenza and rhinovirus infections. (1999) (14)
Amantadine aerosols in normal volunteers: pharmacology and safety testing (1979) (14)
Antiviral monotherapy for hospitalised patients with COVID-19 is not enough (2020) (14)
COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference (2021) (13)
Lymphocyte Subsets in the Nasal Mucosa and Peripheral Blood during Experimental Rhinovirus Infection (1992) (13)
Clinical Virology, Third Edition (2009) (13)
In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1 (1994) (13)
Comparison of radioactive (32P and 35S) and biotinylated probes for detection of cytomegalovirus DNA. (1987) (13)
Respiratory viruses and acute otitis media. (1999) (12)
Pulmonary nocardiosis in AIDS. (1991) (12)
Patient-oriented pandemic influenza research (2009) (12)
Nasal Mucus Weights in Experimental Rhinovirus Infection (1992) (11)
Protective effect of rhinovirus receptor blocking antibody in human fibroblast cells. (1989) (11)
Post-Exposure Influenza Prophylaxis with Oseltamivir (2012) (10)
Psychological stress and the common cold. (1992) (10)
Immunoblot studies to analyze antibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis (1991) (9)
Update on therapy of influenza and rhinovirus infections. (1996) (9)
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment (2021) (9)
Combined Interferon-α2, Rimantadine Hydrochloride, and Ribavirin Inhibition of Influenza Virus Replication In Vitro (1984) (8)
Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection. (2006) (8)
Influenza virus neuraminidase inhibitors: clinical aspects (2001) (8)
The Beneficial Effects of Neuraminidase Inhibitor Drug Therapy on Severe Patient Outcomes During the 2009–2010 Influenza A Virus Subtype H1N1 Pandemic (2012) (8)
Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects (2009) (8)
Influenza in the Elderly (1996) (8)
Therapy of H7N9 pneumonia: current perspectives (2013) (8)
Measurement of rimantadine in plasma by capillary gas chromatography/mass spectrometry with a deuterium-labeled internal standard. (1988) (8)
Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses (2005) (7)
Otologic and Systemic Manifestations of Experimental Influenza a Virus Infection in the Ferret (1995) (7)
RSV Antivirals: Problems and Progress. (2020) (7)
Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011. (2012) (7)
Drug resistance and influenza pandemics (2002) (6)
Tolerance and nasal histopathologic effects of long-term, low-dose intranasal recombinant interferon alpha-2A (Roferon-A). (1987) (6)
Combined Intranasal Ipratropium Bromide and Oxymetazoline in Experimental Rhinovirus Infection (1998) (6)
Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic Potential (2015) (6)
Second isirv antiviral group conference: overview (2013) (6)
A dose response study of hepatitis A vaccine in healthy adults who are > or = 30 years old and weigh > or = 77 kg. (1998) (6)
Editorial Commentary: Host and Viral Factors in Emergent Influenza Virus Infections (2014) (6)
Respiratory Syncytial Virus Antivirals: Problems and Progress (2020) (6)
Lobar collapse with respiratory syncytial virus pneumonitis (2006) (6)
Current research on respiratory viral infections: Fifth International Symposium☆ (2004) (6)
Rhinovirus genetics and virulence: looking for needles in a haystack. (2012) (5)
The Association Of Corticosteroid Therapy And The Outcome Of Critically Ill Patients With The Middle East Respiratory Syndrome (2017) (5)
Live Victoria/75-ts-1[E] Influenza A Virus Vaccines in Adult Volunteers: Role of Hemagglutinin Immunity in Protection Against Illness and Infection Caused by Influenza A Virus (1979) (4)
In vitro Antiviral Activity and Cytotoxicity of Aspirin: Lack of Selective Activity against Influenza a Virus or Rhinovirus (1990) (4)
Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial (2020) (4)
Intranasal Interferons for Control of Respiratory Viral Infections (1988) (4)
Zanamivir. A potent and selective inhibitor of influenza A and B viruses. (1999) (4)
Comparative susceptibilities of strain MRC-5 human embryonic lung fibroblast cells and the Cooney strain of human fetal tonsil cells for isolation of rhinoviruses from clinical specimens (1985) (4)
Advances in the prophylaxis and treatment of influenza illness. Based on a presentation by Frederick G. Hayden, MD. (2000) (4)
Middle ear pressure in preschool age children: influence of respiratory illness, season, and picornavirus or bacteria in the nasopharynx (2007) (3)
Antivirals for influenza: novel agents and approaches. (2008) (3)
Antibiotics and chronic obstructive pulmonary disease. (1987) (3)
Introduction: emerging importance of the rhinovirus (2002) (3)
Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN-αCon1 (1988) (3)
MINIREVIEW Chemotherapy of Rhinovirus Colds (3)
Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials (2022) (2)
Dose-Ranging Safety and Immunogenicity Study of Live Attenuated Varicella-Zoster Virus Vaccine (Oka/Merck) Administered to Adults 60 Years of Age or Older.: GER-3 (2005) (2)
Anti-influenza virus activity of the neuramindase inhibitor 4-guanidinoNeu5Ac2en in cell culture and in human respiratory epithelium (antiviral research 25 (1994) 123–131)☆ (1994) (2)
Respiratory Tract Viral Infections (2006) (2)
The search for therapeutic options for Middle East Respiratory Syndrome (MERS) (2016) (2)
Comparative Antirhinoviral Activities ofSoluble Intercellular Adhesion Molecule-i (sICAM-1) andChimeric ICAM-l/Immunoglobulin (1994) (2)
Clinical and Economic Impact of COVID-19 on Plantation Workers: Preliminary Results from the Guatemala Agricultural Workers and Respiratory Illness Impact (AGRI) Study (2022) (2)
Clinical and Economic Impact of COVID-19 on Agricultural Workers, Guatemala (2022) (2)
Safety and Immunogenicity of a Baculovirus- Expressed Hemagglutinin Influenza Vaccine (2016) (2)
Drug resistance and influenza pandemics (2002) (2)
Modification of encephalomyocarditis virus-induced diabetes in mice by antiviral agents. (1983) (2)
Perspectives in the Use of Antiviral Agents for Prevention and Treatment of Respiratory Virus Infections (1988) (2)
Circular and Cumulative Causation and the Social (2008) (2)
Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN-alpha Con1. (1988) (2)
General Discussion: DISCUSSANTS (1988) (2)
Antiviral Agents Against Respiratory Viruses (2009) (2)
1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPS (2018) (1)
Serotherapy for patients with severe influenza. (2017) (1)
Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 1 (2011) (1)
Faculty Opinions recommendation of A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. (2005) (1)
Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 2 (2011) (1)
Neuraminidase inhibitors: assessment of limitations to greater therapeutic use (2004) (1)
Ribavirin And Interferon For Critically Ill Patients With Middle East Respiratory Coronavirus (mers-Cov) Infection (2015) (1)
XIth International Symposium on Respiratory Viral Infections (2011) (1)
Effects of Naproxen on Experimental Rhinovirus Colds (2020) (1)
Critically Ill Patients With The Middle East Respiratory Coronavirus (mers-Cov) Infection (2015) (1)
Long-Term Tolerance of Intranasal Recombinant Interferon-βSER in Man (1987) (1)
COVID-19: studying the global pandemic – foreword (2020) (1)
Accumulation of segment 6 sgRNAs of influenza A viruses in the presence of neuraminidase inhibitors (2001) (1)
Influenza virus, respiratory syncytial virus, parainfluenza viruses, rhinovirus, and respiratory adenoviruses (1999) (1)
Spotlight on Respiratory Viruses: Introduction (2005) (1)
Introduction: Emerging importance of the rhinovirus☆ (2003) (1)
Cost and the Common Cold (1997) (1)
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences: 356 (1416) (2001) (0)
INS37217 Nasal Spray, a P2Y2 receptor agonist, as a novel treatment for common cold (2004) (0)
Faculty Opinions recommendation of Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. (2005) (0)
Comparative Single-Dose Pharmacokinetics of Amantadine Hydrochloride and Rimantadine Hydrochloride in Young and Elderly Adults (1986) (0)
Treatment Strategies for Novel and Pandemic Influenza (2018) (0)
Outcomes of Influenza with Treatment in Patients with Diabetes: Subgroup Analysis of the Phase 3 CAPSTONE-2 Trial (2021) (0)
Drug resistance and influenza pandemics. Author's reply (2002) (0)
Heterogeneity of treatment effect of interferon-β1b and lopinavir–ritonavir in patients with Middle East respiratory syndrome by cytokine levels (2022) (0)
The ethics of personal stockpiles. Author's reply (2006) (0)
用无神经氨酸酶的甲型流感病毒变异株对雪貂鼻内免疫的保护效果 (2006) (0)
P chain reaction–based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion (1998) (0)
座談会 Influenza: Current issues (2004) (0)
Antivirals for Influenza: Personal Perspectives on Flu Bugs and Drugs (2006) (0)
Antiviral Agents for SARS (2008) (0)
When should we treat respiratory virus infections (1999) (0)
Edinburgh Research Explorer Middle East Respiratory Syndrome (2017) (0)
Naproxen in the treatment of naturally occurring colds: Effect on middle ear pressure (1999) (0)
Critically Ill Patients With The Middle East Respiratory Syndrome (mers): A Multicenter Study (2016) (0)
Cytokine production if circulating lymphocytes from children treated for wheezing in the emergency department (ED) (2004) (0)
Surviving Sepsis Campaign : Rapid Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 ( COVID-19 ) (2020) (0)
Faculty Opinions recommendation of Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. (2005) (0)
Avian Influenza : Current Status (2008) (0)
Rhinovirus and soluble ICAM-1 in nasal washes from children with wheezing or rhinitis in the emergency department (ED) (2005) (0)
The Ethics of Personal Stockpiles (2006) (0)
Explorer Middle East Respiratory Syndrome (2017) (0)
A COVID-19 Pretest Probability Calculator (2021) (0)
Newer influenza antivirals and biotherapeutics (2012) (0)
Mitogenic response of lymphocytes in the presence of serum from rats bearing allogenic tissue implants in the anterior chamber of the eye (1981) (0)
Reply to EC de Haas EC and HJ Luijendijk, Eur J Intern Med. 2019 Apr;62: e8-e9. (2019) (0)
Epstein-Varr virus. (2009) (0)
Influenza: What the Infectious Diseases Practitioner Needs to Know in 2017 (2017) (0)
Future Treatments for Influenza (2014) (0)
Antivíricos (no retrovíricos) (2006) (0)
Comment to: Baloxavir efficacy in North American Adults (2020) (0)
RapidDiagnosis ofInfluenza A andB by24-hFluorescent FocusAssays (1988) (0)
Influenza Late Breaker Abstracts (2009) (0)
Spotlight on respiratory viruses 2012: introduction. (2012) (0)
Current research on respiratory viral infections: XIIth International Symposium. (2012) (0)
Vector control to eliminate artemisinin resistant malaria in the Greater Mekong subregion (2014) (0)
New Approaches to Influenza ChemotherapyInhibitors (1998) (0)
The preceding letter was referred to Dr. Frederick G. Hayden for a reply (1983) (0)
Hospitalized with Influenza A and B infections (2013) (0)
How To Challenge – Current Design, Participant and Microbiological Considerations of Human Volunteer Challenge (2020) (0)
Arthropod-borne falviviruses. (2009) (0)
OralRimantadine Hydrochloride Therapy ofInfluenza A Virus H3N2Subtype Infection inAdults (1986) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Frederick G. Hayden?

Frederick G. Hayden is affiliated with the following schools:

Frederick G. Hayden's Academic­Influence.com Rankings

Frederick G. Hayden's Degrees

Why Is Frederick G. Hayden Influential?

Frederick G. Hayden's Published Works

Published Works

What Schools Are Affiliated With Frederick G. Hayden?

Frederick G. Hayden's AcademicInfluence.com Rankings